hotspot -WSS

hotspot

author：entertainment 2025-08-10 11:42:33 - browse：59

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： DOJ, FTC to increase scrutiny of all types of health care mergers

knowledge

WSS

Readout Newsletter: Merck, J&J, and long Covid

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

New warning issued for rebooking air travel after delays, cancellations

DOJ, FTC to increase scrutiny of all types of health care mergers

Francis Collins on trust in science and how Covid communications failed

Medicare Advantage today, explained in one chart

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

How one medical school became remarkably diverse

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Tori Bowie and the unacceptable rates of Black maternal death

'Reaching a detente': STAT's Helen Branswell on covering Covid

Supreme Court strikes down use of affirmative action

Resistance to cancer drugs: A new genetic explanation

After affirmative action ruling, medical educators look to 'holistic review'

Independent physicians launch a new lobbying group

George Santos makes 1st court appearance after pleading not guilty to 13 counts

States increasingly look to regulate hospital facility fees

focus

Humana cuts profit projections as Medicare Advantage costs soar

Elizabeth Holmes banned from government health programs

Researchers separate signal from noise in heart wearable data

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

India sets sights on home

'Reaching a detente': STAT's Helen Branswell on covering Covid

knowledge

leisure time

knowledge

focus